Differentially expressed miRNAs in cytogenetic and molecular subtypes of pediatric acute myeloid leukemia

Oorschot, Astrid A Danen-van; Kuipers, Jenny E; Arentsen-Peters, Susan T.C.J.M.; Schotte, Diana; Haas, Valérie de; Trka, Jan; Baruchel, André; Reinhardt, Dirk; Pieters, Rob; Zwaan, C. Michel; Heuvel‐Eibrink, Marry M. van den

doi:10.1002/pbc.23279

Cited by 46 publications

(51 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, miR-196b is co-expressed with its neighboring genes HOXA9 and HOXA10 in MLL-rearranged ALL, 57 T-ALL 57 and AML patients. 23 Similar co-activation may explain the high association for miR-10a (positioned in between HOXB4 and HOXB5) as well as miR-196a (encoded in between HOXB9 and HOXB13) with the HOXB cluster as observed in adult 25,71 and childhood AML. 23 It is, however, intriguing that aberrant expression of neighboring genes, genomic aberrations and specific regulatory factors can only explain the minority of dysregulated miRNAs whereas an explanation is still lacking for the majority of aberrantly expressed miRNAs in acute leukemia.…”

Section: Forces That Drive the Dysregulation Of Mirnas In Acute Leukemiamentioning

confidence: 86%

“…18,20 MLL-rearranged AML cases, the oncogenic miR-17-92 cluster was upregulated 21,34,32 whereas the tumor-suppressor miR-29 was downregulated (Table 2). 19,23 MiRNA expression levels are also associated with molecular subtypes of AML, the mutational status and associated gene expression pattern in AML (Table 2). Adult cases with cytogenetically normal (CN)-AML and favorable C/EBPa-mutations demonstrated higher levels of miR-181 (ref.…”

Section: Aberrant Mirna Expression Characterizes Different Cytogenetimentioning

confidence: 99%

“…This shows that miR-21 itself is capable to initiate, maintain and support survival of lymphoma/ leukemia in vivo. 56 Upregulation of miR-196b coincides with HOXA overexpression in pediatric MLL-rearranged precursor B-ALL, HOXAactivated T-ALL 57 and in different subtypes of AML 20,23,30 ( Tables 1 and 2). The high level expression of miR-196b was not predictive for prednisolone resistance in pediatric ALL, albeit MLL-rearranged cases are more resistant to this drug.…”

Section: Oncogenic Mirnasmentioning

confidence: 99%

“…23,25,[50][51][52][53] MiR-155 acts as an oncogene as its introduction in mouse bone marrow resulted in myeloproliferative disorders 54 and B-lineage ALL/lymphoma. 55 The oncogenic effect was mediated by downregulation of SHIP (Src homology 2 domain-containing inositol-5-phosphatase) and C/EBPb.…”

Section: Oncogenic Mirnasmentioning

confidence: 99%

See 3 more Smart Citations

MicroRNAs in acute leukemia: from biological players to clinical contributors

2011

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are involved in the management of hematopoiesis. As a consequence, miRNA dysregulation causes disruption of the hematopoietic system and leukemia may arise. We here comprehensively discuss miRNAs found discriminative for cytogenetic and molecular subtypes of acute leukemia. These miRNAs are either known miRNAs involved in leukemogenesis with proven tumor suppressor or oncogenic activities or are newly identified by high-throughput sequencing with yet unknown function. Furthermore, forces are outlined that drive aberrant miRNA function, which include genetic abnormalities (for example, deletions, translocations and mutations) and epigenetic aberrations (for example, aberrant DNA methylation or histone modifications). Interestingly, leukemia-silenced miRNAs can be re-expressed upon treatment with de-methylating agents. Targeting miRNA expression may serve a therapeutical role, albeit at present this way of targeted therapy is in its infancy. However, emerging knowledge about the biology of miRNAs in leukemia may result into a role for these miRNAs in the diagnosis and treatment of acute leukemia.

show abstract

Section: Forces That Drive the Dysregulation Of Mirnas In Acute Leukemiamentioning

confidence: 86%

Section: Aberrant Mirna Expression Characterizes Different Cytogenetimentioning

confidence: 99%

Section: Oncogenic Mirnasmentioning

confidence: 99%

Section: Oncogenic Mirnasmentioning

confidence: 99%

See 2 more Smart Citations

MicroRNAs in acute leukemia: from biological players to clinical contributors

2011

View full text Add to dashboard Cite

show abstract

“…91 ), down-regulation of miR-196a/b was found in adult MLL rearranged AML (ref. 92 ) and over-expression of miR-181 was associated with a high percentage of blasts in AML with a favorable outcome 93 . A number of studies focused on the role of miR-29 family members in AML.…”

Section: Role Of Mir-29 In Individual Hematopoietic Malignanciesmentioning

confidence: 99%

The role of miR-29 family members in malignant hematopoiesis

Kollinerová¹,

Vassanelli²,

Modrianský³

2014

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

Aims. MicroRNAs of the miR-29 family members were one of the first microRNAs identified as possible therapeutic agents in malignant hematopoiesis. The aim of our review is to summarize the current state of knowledge on miR-29 family members. Methods. We performed literature searches involving miR-29 family members and their relationship to individual hematological malignancies, namely acute myeloid leukemia (AML), chronic lymphoblastic leukemia (CLL) and chronic myeloid leukemia (CML). We also searched for subgroups of hematological malignancies, e.g. multiple myeloma, that are regarded as members of the acute or chronic types of leukemias. Results. A number of genes appear to be regulated by miR-29 family members in various physiological and pathological situations. In our view regulation of Tcl-1, Mcl-1 and DNA methyltransferases is relevant in case of hematological malignancies, hence these are the focus of this review. miR-29 family members also function during normal T-cell and B-cell development. Conclusion. MiR-29 family members appear to govern some general features in commonly heterogenous hematological malignancies and therefore form a potential target for treatment.

show abstract